MED24 deficiency promotes R-loop accumulation and sensitizes to SN-38 in triple-negative breast cancer
The application of DNA topoisomerase I (TOP1) inhibitors in triple-negative breast cancer (TNBC) still needs to be optimized. The principle of synthetic lethality represents a promising strategy to optimize TNBC treatment using SN-38, a representative TOP1 inhibitor and the active metabolite of irinotecan. MED24, yet...